Arlington, MA, United States of America

Ioana Davies

This inventor holds 11 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2014-2020.

USPTO Granted Patents = 11 

% Patents Active = 90.9


 

Average Co-Inventor Count = 20.6

ph-index = 8

Forward Citations = 151(Granted Patents)


Location History:

  • Watertown, MA (US) (2014 - 2015)
  • Arlington, MA (US) (2014 - 2020)

Company Filing History:


Years Active: 2014-2020

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovator in Arlington, MA: Ioana Davies

Introduction:

Ioana Davies, a prolific inventor based in Arlington, MA, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents. With 11 patents to his name, Davies stands as a leading figure in the fight against influenza viruses.

Latest Patents:

Among his latest patents is a series of inhibitors for inhibiting the replication of influenza viruses, reducing their presence in biological samples, and treating influenza in patients. These compounds, represented by Structural Formula (I) or its salt, have shown promise in combatting the spread of this infectious disease.

Career Highlights:

Davies is currently associated with Vertex Pharmaceuticals, Inc., a renowned pharmaceutical company known for its innovative research and development in the healthcare sector. His affiliation with Vertex Pharmaceuticals underscores his dedication to advancing pharmaceutical solutions.

Collaborations:

Throughout his career, Ioana Davies has collaborated closely with esteemed colleagues such as Paul S Charifson and Michael P Clark. Together, they have worked on cutting-edge projects aimed at transforming the landscape of antiviral treatments.

Conclusion:

In conclusion, Ioana Davies' pioneering work in developing inhibitors for influenza viruses showcases his commitment to medical innovation. His patents and collaborations exemplify his profound impact on the pharmaceutical industry, leaving a lasting legacy in the realm of antiviral research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…